Repligen Corp. 10-Q Summary: Quarter Ended June 30, 1999
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 1999, for Repligen Corporation, a biotechnology company developing drugs for neurological diseases, organ transplantation, and cancer. The company also manufactures products for therapeutic antibody purification. The financial statements are unaudited.
Key Financial Metrics
| Metric | Q2 1999 | Q2 1998 |
|---|---|---|
| Total Revenues | $688,168 | $592,423 |
| Net Loss | $(422,587) | $(342,860) |
| Net Loss Per Share (Basic/Diluted) | $(0.02) | $(0.02) |
| Cash and Cash Equivalents (End of Period) | $11,817,472 | $4,286,573 |
| Net Cash Used in Operating Activities | $(275,812) | $(383,019) |
| Net Cash Provided by Financing Activities | $8,905,358 | $0 |
| Working Capital | $12,352,880 | Filing text does not provide clear value for Q2 1998 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 16% to approximately $688,000, driven primarily by a 41% increase in research and development revenue due to a licensing payment.
- Expense Increases: Total expenses rose 18% to approximately $1.11 million. Cost of products sold increased 75% (from $112,000 to $196,000) due to startup costs for a manufacturing contract with Amersham Pharmacia Biotech.
- Liquidity Surge: Cash and cash equivalents increased by $8.57 million, primarily due to a private placement of 3.6 million shares of common stock for $9 million (net proceeds of $8.9 million) closed on June 23, 1999.
- Product Margins: Cost of products sold as a percentage of product revenue increased from 49% in Q2 1998 to 85% in Q2 1999.
Outlook, Risks, and Management Commentary
- Capital Resources: Management believes the $8.9 million in net proceeds from the private placement will satisfy working capital and capital expenditure requirements for the next 24 months.
- Product Pipeline: The company is advancing clinical trials for secretin (autism treatment) and CTLA4-Ig (organ transplant/autoimmune disease treatment). A ten-year supply agreement for recombinant Protein A with Amersham Pharmacia Biotech was entered into in December 1998.
- Legal Contingency: Repligen filed a complaint regarding inventorship of patents related to CTLA4. The complaint was dismissed without prejudice on July 13, 1999, citing a lack of legal standing. Repligen intends to pursue the correction of inventorship, noting that failure to obtain shared ownership could restrict commercialization of CTLA4-Ig.
- Year 2000 Compliance: The company expects full Year 2000 compliance by the end of 1999 with estimated costs not exceeding $50,000. No contingency plan exists yet if compliance is not achieved timely.
Investor Verification Checklist
- Verify the status and potential outcome of the dismissed inventorship lawsuit regarding CTLA4 patents and its impact on future commercialization rights.
- Confirm the sustainability of the 85% cost of goods sold ratio for product revenue as the Amersham Pharmacia Biotech manufacturing contract ramps up.
- Monitor the progress of clinical trials for secretin and CTLA4-Ig, as future revenue is heavily dependent on successful clinical results and regulatory approval.
- Assess the company's ability to secure additional financing if the $8.9 million raised is insufficient to cover the anticipated increase in operating costs for fiscal 2000.